{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:39:53Z","timestamp":1792705193919,"version":"4.5.0"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.intimp.2021.107763","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T22:13:48Z","timestamp":1620339228000},"page":"107763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages"],"prefix":"10.1016","volume":"96","author":[{"given":"Hamid","family":"Motamedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzie Mahdizade","family":"Ari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3797-1516","authenticated-orcid":false,"given":"Shirin","family":"Dashtbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Fathollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Hossainpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhoushang","family":"Alvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-2413","authenticated-orcid":false,"given":"Ramin","family":"Abiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/pathogens9050331","article-title":"The human coronavirus disease COVID-19: its origin, characteristics, and insights, into potential drugs and its mechanisms","volume":"9","author":"Alanagreh","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2021.107763_b0010","unstructured":"WHO, Weekly epidemiological update on COVID-19 2021. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---31-march-2021. (Accessed 30 March 2021."},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b0015","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1099\/jmm.0.001231","article-title":"Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study","volume":"69","author":"Khan","year":"2020","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.intimp.2021.107763_b0020","doi-asserted-by":"crossref","unstructured":"L.M. Trujillo Gittermann, S.N. Valenzuela Feris, A. von Oetinger Giacoman, Relation between COVID-19 and Guillain-Barr\u00e9 syndrome in adults. Systematic review, Neurologia (Barcelona, Spain) 35(9) (2020) 646-654.","DOI":"10.1016\/j.nrleng.2020.07.005"},{"key":"10.1016\/j.intimp.2021.107763_b0025","doi-asserted-by":"crossref","unstructured":"K. Matsushita, B. Marchandot, L. Jesel, P. Ohlmann, O. Morel, Impact of COVID-19 on the cardiovascular system: a review, Journal of clinical medicine 9(5) (2020) 1407.","DOI":"10.3390\/jcm9051407"},{"issue":"10223","key":"10.1016\/j.intimp.2021.107763_b0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0035","first-page":"157","article-title":"The COVID-19, epidemiology, clinic and prevention","volume":"21","author":"Antonelli","year":"2020","journal-title":"Curr. Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Therapy"},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"6494","key":"10.1016\/j.intimp.2021.107763_b0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"issue":"6483","key":"10.1016\/j.intimp.2021.107763_b0055","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6499","key":"10.1016\/j.intimp.2021.107763_b0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"6497","key":"10.1016\/j.intimp.2021.107763_b0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct. Target. Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"7830","key":"10.1016\/j.intimp.2021.107763_b0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"10249","key":"10.1016\/j.intimp.2021.107763_b0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"issue":"10249","key":"10.1016\/j.intimp.2021.107763_b0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.intimp.2021.107763_b0105","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0110","first-page":"1","article-title":"COVID-19 in early 2021: current status and looking forward","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Therapy"},{"key":"10.1016\/j.intimp.2021.107763_b0115","unstructured":"WHO, Draft landscape and tracker of COVID-19 candidate vaccines, 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. (Accessed 2 April 2021."},{"key":"10.1016\/j.intimp.2021.107763_b0120","first-page":"1","article-title":"Immunity, endothelial injury and complement-induced coagulopathy in COVID-19","author":"Perico","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.107763_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/08830185.2020.1844195","article-title":"Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome","volume":"40","author":"Borges","year":"2021","journal-title":"Int. Rev. Immunol."},{"issue":"7816","key":"10.1016\/j.intimp.2021.107763_b0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-00571-x","article-title":"SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response","volume":"18","author":"Fu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2021.107763_b0140","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2021.107763_b0145","article-title":"The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions","volume":"118075","author":"Behl","year":"2020","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0150","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/angiotensin-(1\u20137)\/Mas receptor axis: evidence from basic and clinical research","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.intimp.2021.107763_b0155","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2021.107763_b0160","doi-asserted-by":"crossref","unstructured":"T.M. Clausen, D.R. Sandoval, C.B. Spliid, J. Pihl, H.R. Perrett, C.D. Painter, A. Narayanan, S.A. Majowicz, E.M. Kwong, R.N. McVicar, SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2, Cell 183(4) (2020) 1043-1057. e15.","DOI":"10.1016\/j.cell.2020.09.033"},{"key":"10.1016\/j.intimp.2021.107763_b0165","article-title":"The structural basis of accelerated host cell entry by SARS-CoV-2","author":"Seyran","year":"2020","journal-title":"FEBS J."},{"issue":"21","key":"10.1016\/j.intimp.2021.107763_b0170","doi-asserted-by":"crossref","first-page":"11116","DOI":"10.1128\/JVI.01360-15","article-title":"Genome-wide screen reveals valosin-containing protein requirement for coronavirus exit from endosomes","volume":"89","author":"Wong","year":"2015","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.intimp.2021.107763_b0180","doi-asserted-by":"crossref","unstructured":"M. Thoms, R. Buschauer, M. Ameismeier, L. Koepke, T. Denk, M. Hirschenberger, H. Kratzat, M. Hayn, T. Mackens-Kiani, J. Cheng, Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2, bioRxiv (2020).","DOI":"10.1101\/2020.05.18.102467"},{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0185","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0190","article-title":"Toll-like receptors and COVID-19: a two-faced story with an exciting ending, Future","author":"Onofrio","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107763_b0195","article-title":"Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review","volume":"173620","author":"Yarmohammadi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05647-7","article-title":"Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study","volume":"20","author":"Cattelan","year":"2020","journal-title":"BMC Infect. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2021.107763_b0205","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41423-020-0514-8","article-title":"SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70","volume":"17","author":"Jiang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107763_b0210","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200678","article-title":"The many faces of the anti-COVID immune response","volume":"217","author":"Vardhana","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0215","first-page":"56","article-title":"Cytokine release syndrome, Journal for Immunotherapy of","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2021.107763_b0220","article-title":"Neutrophils: their role in innate and adaptive immunity","author":"Rosales","year":"2016","journal-title":"Hindawi"},{"issue":"14","key":"10.1016\/j.intimp.2021.107763_b0225","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b0230","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"Veras","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine Storms: Understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107763_b0240","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53725","article-title":"Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation","volume":"9","author":"Marchingo","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2021.107763_b0245","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3389\/fimmu.2020.02132","article-title":"Cytokine Storm in COVID-19: \u201cWhen You Come Out of the Storm, You Won't Be the Same Person Who Walked in\u201d","volume":"11","author":"Castelli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0250","first-page":"1659","article-title":"Targeting macrophages as a therapeutic option in COVID-19","volume":"11","author":"Gracia-Hernandez","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107763_b0255","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fimmu.2020.01312","article-title":"The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?","volume":"11","author":"Abassi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173547","article-title":"Macrophage responses associated with COVID-19: A pharmacological perspective","volume":"887","author":"Booz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107763_b0265","first-page":"1","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580641","article-title":"Covid-19: Perspectives on Innate Immune Evasion","volume":"11","author":"Taefehshokr","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0275","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-3083.2002.01053.x","article-title":"NK cells, MHC class I molecules and the missing self","volume":"55","author":"K\u00e4rre","year":"2002","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0280","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2021.107763_b0285","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.3390\/ijms21176351","article-title":"Natural Killer Cell Dysfunction and Its Role in COVID-19","volume":"21","author":"van Eeden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2021.107763_b0290","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling Cytokine Storm Is Vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"issue":"S1","key":"10.1016\/j.intimp.2021.107763_b0295","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1710-1492-7-S1-S1","article-title":"An introduction to immunology and immunopathology","volume":"7","author":"Warrington","year":"2011","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0300","article-title":"T-cell dysregulation in COVID-19","author":"Kalfaoglu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2021.107763_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02037","article-title":"The immune response and immunopathology of COVID-19","volume":"11","author":"Mortaz","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107763_b0310","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.177.4.2138","article-title":"Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes","volume":"177","author":"Zhou","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0315","first-page":"1","article-title":"Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses","author":"O\u2019Connell","year":"2020","journal-title":"Hum. Vacc. Immunotherap."},{"key":"10.1016\/j.intimp.2021.107763_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"53","key":"10.1016\/j.intimp.2021.107763_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe8063","article-title":"The known unknowns of T cell immunity to COVID-19","volume":"5","author":"Karlsson","year":"2020","journal-title":"Sci. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2021.107763_b0330","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1111\/jcmm.15771","article-title":"Naturally activated adaptive immunity in COVID-19 patients","volume":"24","author":"Yang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0335","first-page":"1","article-title":"Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis","author":"Kiss","year":"2020","journal-title":"Med. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0340","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerging Microbes Infect."},{"issue":"9","key":"10.1016\/j.intimp.2021.107763_b0345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T cell responses in patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0350","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.17034","article-title":"Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients","volume":"191","author":"Bellesi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2021.107763_b0355","doi-asserted-by":"crossref","unstructured":"Y. Yang, F. Peng, R. Wang, K. Guan, T. Jiang, G. Xu, J. Sun, C. Chang, The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China, J. Autoimmunity (2020) 102434.","DOI":"10.1016\/j.jaut.2020.102434"},{"key":"10.1016\/j.intimp.2021.107763_b0360","article-title":"Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms","author":"Jafarzadeh","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0365","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6508","key":"10.1016\/j.intimp.2021.107763_b0375","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1126\/science.abc8665","article-title":"Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2","volume":"369","author":"Thoms","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107763_b0380","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fimmu.2019.00249","article-title":"Molecular Basis of the Differentiation and Function of Virus Specific Follicular Helper CD4+ T Cells","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0385","doi-asserted-by":"crossref","unstructured":"T. Sekine, A. Perez-Potti, O. Rivera-Ballesteros, K. Str\u00e5lin, J.-B. Gorin, A. Olsson, S. Llewellyn-Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell 183(1) (2020) 158\u2013168.e14.","DOI":"10.1016\/j.cell.2020.08.017"},{"key":"10.1016\/j.intimp.2021.107763_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01817","article-title":"The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies","volume":"11","author":"Frederiksen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b0395","doi-asserted-by":"crossref","unstructured":"P. Martinez-Fleta, A. Alfranca, I. Gonz\u00e1lez-\u00c1lvaro, J.M. Casasnovas, D. Fern\u00e1ndez-Soto, G. Esteso, Y. C\u00e1ceres-Martell, S. Gardeta, S. Prat, T. Mateu-Alberoa, SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in serum and saliva of COVID-19-seropositive individuals, (2020).","DOI":"10.1101\/2020.07.16.20155853"},{"issue":"13","key":"10.1016\/j.intimp.2021.107763_b0400","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jama.2020.16656","article-title":"COVID-19 and the Path to Immunity","volume":"324","author":"Stephens","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2021.107763_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study","author":"Padoan","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0410","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti\u2013SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0415","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/iid3.367","article-title":"Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2","volume":"9","author":"Mveang Nzoghe","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.intimp.2021.107763_b0420","article-title":"High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa","author":"Tso","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.107763_b0425","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3389\/fimmu.2020.586984","article-title":"Potential cross-reactive immunity to SARS-CoV-2 from common human pathogens and vaccines","volume":"11","author":"Reche","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0430","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","author":"Poland","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2021.107763_b0440","article-title":"Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines","volume":"111330","author":"Awadasseid","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"396","key":"10.1016\/j.intimp.2021.107763_b0445","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0450","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12539-020-00376-6","article-title":"Deep learning based drug screening for novel coronavirus 2019-nCov","volume":"12","author":"Zhang","year":"2020","journal-title":"Interdiscip. Sci.: Comput. Life Sci."},{"key":"10.1016\/j.intimp.2021.107763_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.577387","article-title":"Identifying effective antiviral drugs against SARS-CoV-2 by drug repositioning through virus-drug association prediction","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"issue":"7824","key":"10.1016\/j.intimp.2021.107763_b0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell reports"},{"issue":"25","key":"10.1016\/j.intimp.2021.107763_b0475","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0480","doi-asserted-by":"crossref","unstructured":"M.G.S. Borba, F.F.A. Val, V.S. Sampaio, M.A.A. Alexandre, G.C. Melo, M. Brito, M.P.G. Mour\u00e3o, J.D. Brito-Sousa, D. Ba\u00eda-da-Silva, M.V.F. Guerra, Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw. Open 3(4) (2020) e208857\u2013e208857.","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discovery"},{"issue":"7","key":"10.1016\/j.intimp.2021.107763_b0490","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-020-2721-8","article-title":"Is hydroxychloroquine beneficial for COVID-19 patients?","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2021.107763_b0495","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2021.107763_b0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2005.01.003","article-title":"Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus","volume":"66","author":"Saijo","year":"2005","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0510","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0960-9822(03)00290-2","article-title":"Superior underwater vision in a human population of sea gypsies","volume":"13","author":"Gisl\u00e9n","year":"2003","journal-title":"Curr. Biol."},{"issue":"10259","key":"10.1016\/j.intimp.2021.107763_b0515","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157489106778777673","article-title":"Advances in the development of inactivated virus vaccines","volume":"1","author":"Stauffer","year":"2006","journal-title":"Recent Pat. Anti-Infect. Drug Discov."},{"key":"10.1016\/j.intimp.2021.107763_b0525","series-title":"Animal Biotechnology","first-page":"491","article-title":"Chapter 26 - Vaccines: Present Status and Applications","author":"Yadav","year":"2014"},{"key":"10.1016\/j.intimp.2021.107763_b0530","series-title":"Vaccine Analysis: Strategies, Principles, and Control","first-page":"45","article-title":"Inactivated Viral Vaccines","author":"Sanders","year":"2015"},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0535","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/pathogens9110928","article-title":"SARS-CoV-2 vaccines: Inactivation by gamma irradiation for T and B cell immunity","volume":"9","author":"Mullbacher","year":"2020","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0540","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of SARS-CoV-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2021.107763_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2021.107763_b0550","doi-asserted-by":"crossref","unstructured":"W. Sun, S. McCroskery, W.C. Liu, S.R. Leist, Y. Liu, R.A. Albrecht, S. Slamanig, J. Oliva, F. Amanat, A. Sch\u00e4fer, K.H. Dinnon, 3rd, B.L. Innis, A. Garc\u00eda-Sastre, F. Krammer, R.S. Baric, P. Palese, A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine, Vaccines 8(4) (2020) 2020.07.30.229120.","DOI":"10.3390\/vaccines8040771"},{"key":"10.1016\/j.intimp.2021.107763_b0555","unstructured":"dynavax, Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19, 2020. https:\/\/investors.dynavax.com\/news-releases\/news-release-details\/valneva-and-dynavax-announce-collaboration-advance-vaccine. (Accessed 22 April 2020)."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0560","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1038\/s41598-021-83930-6","article-title":"Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates","volume":"11","author":"Sir Karakus","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.107763_b0565","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2021.107763_b0570","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3389\/fimmu.2019.01250","article-title":"Attenuation of human respiratory viruses by synonymous genome recoding","volume":"10","author":"Le Nou\u00ebn","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0575","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2899","article-title":"Synonymous but not the same: the causes and consequences of codon bias","volume":"12","author":"Plotkin","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.intimp.2021.107763_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107586","article-title":"Mechanism of virus attenuation by codon pair deoptimization","volume":"31","author":"Groenke","year":"2020","journal-title":"Cell Reports"},{"issue":"7","key":"10.1016\/j.intimp.2021.107763_b0585","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1093\/nar\/gku075","article-title":"The influence of CpG and UpA dinucleotide frequencies on RNA virus replication and characterization of the innate cellular pathways underlying virus attenuation and enhanced replication","volume":"42","author":"Atkinson","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b0590","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nmicrobiol.2017.88","article-title":"Attenuation of RNA viruses by redirecting their evolution in sequence space","volume":"2","author":"Moratorio","year":"2017","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.intimp.2021.107763_b0595","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0600","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.micinf.2014.12.006","article-title":"Advancements in the development of subunit influenza vaccines","volume":"17","author":"Zhang","year":"2015","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2021.107763_b0605","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Lanying Du, Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0610","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0615","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020153","article-title":"Progress and Prospects on Vaccine Development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b0620","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1042\/BC20070173","article-title":"Viral detection by electron microscopy: past, present and future","volume":"100","author":"Roingeard","year":"2008","journal-title":"Biol. Cell"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0625","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1574-6968.1994.tb06778.x","article-title":"Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells","volume":"117","author":"Cann","year":"1994","journal-title":"FEMS Microbiol. Lett."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.107763_b0630","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000150475","article-title":"Papillomavirus-like particles for serology and vaccine development","volume":"39","author":"Kirnbauer","year":"1996","journal-title":"Intervirology"},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0635","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines4020012","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.107763_b0640","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vetmic.2015.02.021","article-title":"Protective immunity against nervous necrosis virus in convict grouper Epinephelus septemfasciatus following vaccination with virus-like particles produced in yeast Saccharomyces cerevisiae","volume":"177","author":"Wi","year":"2015","journal-title":"Vet. Microbiol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005203","article-title":"Crystal structures of a piscine betanodavirus: mechanisms of capsid assembly and viral infection","volume":"11","author":"Chen","year":"2015","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/j.intimp.2021.107763_b0650","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00705-008-0150-6","article-title":"Role of the DxxDxD motif in the assembly and stability of betanodavirus particles","volume":"153","author":"Wu","year":"2008","journal-title":"Arch. Virol."},{"key":"10.1016\/j.intimp.2021.107763_b0655","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","author":"Mohsen","year":"2017","journal-title":"Seminars in immunology, Elsevier"},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA Vaccines-How Far From Clinical Use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0665","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b0670","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0675","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107763_b0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA\/MVA Vaccinees: A Phase I Randomized Trial","volume":"10","author":"Nilsson","year":"2015","journal-title":"PLoS ONE"},{"issue":"50","key":"10.1016\/j.intimp.2021.107763_b0685","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2021.107763_b0690","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2021.107763_b0695","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3389\/fimmu.2020.01880","article-title":"The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development","volume":"11","author":"Alturki","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2021.107763_b0700","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/vaccines8030404","article-title":"COVID-19: Mechanisms of Vaccination and Immunity","volume":"8","author":"Speiser","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2021.107763_b0705","unstructured":"Z. Cadila, Zydus Cadila Announces Completion of Dosing in Phase I Clinical Trial of ZyCoV-D, 2020. https:\/\/zyduscadila.com\/public\/pdf\/pressrelease\/Press-Release-ZyCoV-D.pdf (Accessed 05 August 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0710","unstructured":"T. Thacker, Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials, 2020. https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/zydus-cadila-to-test-zycov-d-on-30000-patients-in-phase-3-trials\/articleshow\/79088859.cms?from=mdr (Accessed 07 November 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0715","doi-asserted-by":"crossref","unstructured":"G. Montel Mendoza, S.E. Pasteris, M.C. Otero, M. Fatima Nader\u2010Mac\u00edas, Survival and beneficial properties of lactic acid bacteria from raniculture subjected to freeze\u2010drying and storage, J. Appl. Microbiol. 116(1) (2014) 157\u2013166.","DOI":"10.1111\/jam.12359"},{"key":"10.1016\/j.intimp.2021.107763_b0720","unstructured":"K.R. Emary, T. Golubchik, P.K. Aley, C.V. Ariani, B.J. Angus, S. Bibi, B. Blane, D. Bonsall, P. Cicconi, S. Charlton, Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012\/01 (B. 1.1. 7), (2021)."},{"key":"10.1016\/j.intimp.2021.107763_b0725","unstructured":"P.H. Services, CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12), 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04627675?term=DNA+vaccines+against+SARS-CoV2&cond=COVID+19+SARS-CoV2&draw=2+DNA+candidate+vaccine+in+pre-clinical+trial+stage (Accessed 15 March 2021."},{"key":"10.1016\/j.intimp.2021.107763_b0730","unstructured":"Cambridge, Cambridge-developed SARS-CoV-2 vaccine receives \u00a31.9million from UK government for clinical trial, 2020. https:\/\/www.cam.ac.uk\/research\/news\/cambridge-developed-sars-cov-2-vaccine-receives-ps19million-from-uk-government-for-clinical-trial (Accessed 26 August 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0735","unstructured":"CanSino, CanSinoBIO\u2019s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China, 2020. http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/408.html (Accessed 17 March 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0740","article-title":"COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies","volume":"173751","author":"Rawat","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107763_b0745","doi-asserted-by":"crossref","unstructured":"D.Y. Logunov, I.V. Dolzhikova, D.V. Shcheblyakov, A.I. Tukhvatulin, O.V. Zubkova, A.S. Dzharullaeva, A.V. Kovyrshina, N.L. Lubenets, D.M. Grousova, A.S. Erokhova, A.G. Botikov, F.M. Izhaeva, O. Popova, T.A. Ozharovskaya, I.B. Esmagambetov, I.A. Favorskaya, D.I. Zrelkin, D.V. Voronina, D.N. Shcherbinin, A.S. Semikhin, Y.V. Simakova, E.A. Tokarskaya, D.A. Egorova, M.M. Shmarov, N.A. Nikitenko, V.A. Gushchin, E.A. Smolyarchuk, S.K. Zyryanov, S.V. Borisevich, B.S. Naroditsky, A.L. Gintsburg, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet (London, England) 397(10275) (2021) 671\u2013681.","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"10.1016\/j.intimp.2021.107763_b0750","unstructured":"U.o. Sydney, University of Sydney to advance COVID-19 DNA vaccine to human trials, 2020. https:\/\/www.sydney.edu.au\/news-opinion\/news\/2020\/09\/24\/university-of-sydney-to-advance-covid-19-dna-vaccine-to--human-t.html. (Accessed 24 September 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0755","unstructured":"S. BROOK, Applied DNA and Takis Biotech\/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate, 2020. https:\/\/www.evvivax.com\/index.php\/news\/72-applied-dna-and-takis-biotech-evvivax-to-launch-clinical-trial-for-veterinary-use-of-linear-covid-19-vaccine-candidate. (Accessed 16 September 2020."},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b0760","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cei.13517","article-title":"Vaccines for COVID-19","volume":"202","author":"Tregoning","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b0765","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2021.107763_b0770","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107763_b0775","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Therapy"},{"key":"10.1016\/j.intimp.2021.107763_b0785","doi-asserted-by":"crossref","unstructured":"P. Yuan, P. Ai, Y. Liu, Z. Ai, Y. Wang, W. Cao, X. Xia, J.C. Zheng, Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis, medRxiv (2020).","DOI":"10.1101\/2020.11.03.20224998"},{"key":"10.1016\/j.intimp.2021.107763_b0790","unstructured":"R. Calandra, As Vaccines Near the Possible-Approval Line, New Challenges Await 2020. https:\/\/www.medicaldaily.com\/vaccines-near-possible-approval-line-new-challenges-await-457497. (Accessed 20 November 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.intimp.2021.107763_b0800","doi-asserted-by":"crossref","unstructured":"S. Pascolo, Vaccination with messenger RNA (mRNA), Toll-like receptors (TLRs) and innate immunity, Springer, 2008, pp. 221\u2013235.","DOI":"10.1007\/978-3-540-72167-3_11"},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b0805","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14712598.4.8.1285","article-title":"Messenger RNA-based vaccines","volume":"4","author":"Pascolo","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2021.107763_b0810","unstructured":"E.O.-O. Hannah Ritchie, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie Macdonald, Charlie Giattino, Cameron Appel and Max Roser, Coronavirus (COVID-19) Vaccinations, 2021. https:\/\/ourworldindata.org\/covid-vaccinations. (Accessed 18 April 2021)."},{"key":"10.1016\/j.intimp.2021.107763_b0815","unstructured":"L.S.o.H.T. Medicine, Equity of vaccine roll-out, 2021. https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/. (Accessed 31 March 2021)."},{"key":"10.1016\/j.intimp.2021.107763_b0820","unstructured":"T. Zaks, Protocol mRNA-1273-P301, Amendment 3. 2020, 2020. https:\/\/www.modernatx.com\/sites\/default\/files\/mRNA-1273-P301-Protocol.pdf. (Accessed 20 August 2020."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00431-001-0853-0","article-title":"Immediate allergic reactions after vaccinations\u2013a post-marketing surveillance review","volume":"161","author":"Zent","year":"2002","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b0830","first-page":"107","article-title":"The race for a COVID-19 vaccine, Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire","volume":"54","author":"Lavigne","year":"2020","journal-title":"JCHD"},{"issue":"11","key":"10.1016\/j.intimp.2021.107763_b0835","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"issue":"25","key":"10.1016\/j.intimp.2021.107763_b0840","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0845","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41594-020-0483-8","article-title":"Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation","volume":"27","author":"McCallum","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0850","doi-asserted-by":"crossref","first-page":"25","DOI":"10.29252\/vacres.7.1.25","article-title":"The Potential of Self-amplifying RNA Vaccines for Infectious Diseases and COVID-19","volume":"7","author":"Lundstrom","year":"2020","journal-title":"Vaccine Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0855","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12864-019-5909-5","article-title":"Reference genome and comparative genome analysis for the WHO reference strain for Mycobacterium bovis BCG Danish, the present tuberculosis vaccine","volume":"20","author":"Borgers","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.intimp.2021.107763_b0860","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijid.2021.03.050","article-title":"Interim estimates in null models of COVID-19 vaccine effectiveness","volume":"106","author":"Lisewski","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.107763_b0865","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.107763_b0870","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0875","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.intimp.2021.107763_b0880","unstructured":"Arcturus, Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1\/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore, 2020. https:\/\/ir.arcturusrx.com\/news-releases\/news-release-details\/arcturus-therapeutics-announces-positive-interim-arct-021-lunar. (Accessed 9 November 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0885","unstructured":"J. Fletcher, Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women, 2020. https:\/\/www.isrctn.com\/ISRCTN17072692. (Accessed 27 July 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0890","unstructured":"Calif, Amyris and The Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application, 2020. https:\/\/investors.amyris.com\/2020-07-27-Amyris-and-The-Infectious-Disease-Research-Institute-Partner-to-Advance-Novel-RNA-Vaccine-Platform-Beginning-With-COVID-19-Application. (Accessed 27 July 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0895","unstructured":"S.J.U. Fudan University, and RNACure Biopharma, Vaccine against COVID-19, 2020. https:\/\/www.genengnews.com\/covid-19-candidates\/fudan-university-shanghai-jiaotong-university-and-rnacure-biopharma\/. (Accessed 18 May 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0900","unstructured":"U.o. Washington, HDT-301 (also called repRNA-CoV2S), 2020. https:\/\/www.genengnews.com\/covid-19-candidates\/university-of-washington-uw-medicine-and-hdt-bio-hdt-301\/. (Accessed 3 August 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0905","unstructured":"C. Rademacher, Corona: vaccination without a needle?, 2020. https:\/\/www.mpg.de\/14807464\/0511-mpin-116799-corona-vaccination-via-the-skin. (Accessed 13 May 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0910","unstructured":"COVID-19 Vaccine, AAVCOVID. https:\/\/masseyeandear.org\/covid-19\/vaccine."},{"key":"10.1016\/j.intimp.2021.107763_b0915","unstructured":"GeneOne, GeneOne Life Science and Houston Methodist to develop a COVID-19 vaccine, 2020. (Accessed 17 March 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0920","unstructured":"C. Bio, Chimeron Bio Appoints CEO of Evox Therapeutics and Former CSO of Moderna, Dr. Antonin de Fougerolles to Its Scientific Advisory Board, 2020 https:\/\/www.biospace.com\/article\/releases\/chimeron-bio-appoints-ceo-of-evox-therapeutics-and-former-cso-of-moderna-dr-antonin-de-fougerolles-to-its-scientific-advisory-board\/. (Accessed 7 December 2020."},{"key":"10.1016\/j.intimp.2021.107763_b0925","doi-asserted-by":"crossref","unstructured":"T. Zaichuk, Y. Nechipurenko, A. Adzhubey, S. Onikienko, V. Chereshnev, S. Zainutdinov, G. Kochneva, S. Netesov, O. Matveeva, The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector, Mol. Biol. (2020) 1\u201315.","DOI":"10.1134\/S0026893320060151"},{"key":"10.1016\/j.intimp.2021.107763_b0930","doi-asserted-by":"crossref","unstructured":"M. Bakhiet, S. Taurin, SARS-CoV-2: Targeted managements and vaccine development, Cytokine & growth factor reviews (2020).","DOI":"10.1016\/j.cytogfr.2020.11.001"},{"key":"10.1016\/j.intimp.2021.107763_b0935","doi-asserted-by":"crossref","unstructured":"N.S.H. RW, Progress and prospects: immune responses to viral vectors Gene Ther. 17295304. Nayak, S., Herzog, RW (2010). Progress and prospects: immune responses to viral vectors, Gene Therapy 17 (2010) 295\u2013304.","DOI":"10.1038\/gt.2009.148"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0940","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141332","article-title":"Effect of prolonged radiotherapy treatment time on survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107763_b0950","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2021.107763_b0955","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/vaccines8040649","article-title":"COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response","volume":"8","author":"Jain","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2021.107763_b0960","unstructured":"FDA, First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response, 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. (Accessed 19 December 2019."},{"issue":"5","key":"10.1016\/j.intimp.2021.107763_b0965","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2021.107763_b0970","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","article-title":"Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein","volume":"452","author":"Escriou","year":"2014","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b0975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188453","article-title":"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments","volume":"13","author":"Noyce","year":"2018","journal-title":"PLoS ONE"},{"issue":"18","key":"10.1016\/j.intimp.2021.107763_b0980","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1128\/JVI.00945-06","article-title":"Genome of horsepox virus","volume":"80","author":"Tulman","year":"2006","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b0985","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates","volume":"88","author":"Clarke","year":"2014","journal-title":"J. Virol."},{"issue":"10068","key":"10.1016\/j.intimp.2021.107763_b0990","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"The Lancet"},{"issue":"7830","key":"10.1016\/j.intimp.2021.107763_b0995","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"10267","key":"10.1016\/j.intimp.2021.107763_b1000","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"The Lancet"},{"issue":"10269","key":"10.1016\/j.intimp.2021.107763_b1005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"issue":"10267","key":"10.1016\/j.intimp.2021.107763_b1010","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10269","key":"10.1016\/j.intimp.2021.107763_b1015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2021.107763_b1020","unstructured":"Oxford, Oxford AstraZeneca vaccine to be sold to developing countries at cost price, 2020. https:\/\/www.theguardian.com\/global-development\/2020\/nov\/23\/oxford-astrazeneca-results-covid-vaccine-developing-countries. (Accessed 23 November 2020."},{"key":"10.1016\/j.intimp.2021.107763_b1025","unstructured":"RESEARCH PROJECTS TO RESPOND TO SARS-COV2 PANDEMIC CHALLENGES AT THE CNB-CSIC. https:\/\/www.cnb.csic.es\/index.php\/en\/research\/sars-cov2-research."},{"issue":"10255","key":"10.1016\/j.intimp.2021.107763_b1030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2021.107763_b1035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","author":"Logunov","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2021.107763_b1040","unstructured":"Johnson, Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate, 2020. https:\/\/www.jnj.com\/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate. (Accessed 15 November 2020)."},{"key":"10.1016\/j.intimp.2021.107763_b1045","unstructured":"ImmunityBio, COVID-19 Vaccination Using a 2nd Generation (E1\/E2B\/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04591717. (Accessed 30 March 2021."},{"issue":"10","key":"10.1016\/j.intimp.2021.107763_b1050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.micinf.2020.09.004","article-title":"Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system","volume":"22","author":"de Queiroz","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2021.107763_b1055","unstructured":"G. Gasaatura, Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine, 2020. (Accessed 14 October 2020)."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b1060","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2013-2218","article-title":"Acute lower respiratory infection among Bacille Calmette-Gu\u00e9rin (BCG)\u2013vaccinated children","volume":"133","author":"Hollm-Delgado","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b1065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4269\/ajtmh.2009.81.378","article-title":"Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG\/Leishmania antigens","volume":"81","author":"Pereira","year":"2009","journal-title":"Am. J. Trop. Med. Hygiene"},{"issue":"4","key":"10.1016\/j.intimp.2021.107763_b1070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.imbio.2010.09.003","article-title":"The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells","volume":"216","author":"Li","year":"2011","journal-title":"Immunobiology"},{"issue":"7","key":"10.1016\/j.intimp.2021.107763_b1075","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1128\/iai.55.7.1707-1714.1987","article-title":"Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice","volume":"55","author":"Fortier","year":"1987","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2021.107763_b1080","unstructured":"GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development."},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b1085","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/infdis\/jiv332","article-title":"BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study","volume":"212","author":"Leentjens","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.107763_b1090","unstructured":"M. Vaughan, Valo Therapeutics to Support Development of a Pan \u2013 Coronavirus Vaccine, 2020. https:\/\/www.valotx.com\/article\/valo-therapeutics-support-development-pan-coronavirus-vaccine. (Accessed 27th April 2020."},{"key":"10.1016\/j.intimp.2021.107763_b1095","unstructured":"Valo Therapeutics to Support Development of a Pan \u2013 Coronavirus Vaccine, 27th April 2020. https:\/\/www.valotx.com\/article\/valo-therapeutics-support-development-pan-coronavirus-vaccine."},{"key":"10.1016\/j.intimp.2021.107763_b1100","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2021.107763_b1110","article-title":"Clinical value anti-SARS-COV-2 serum IgA titration in patients with COVID-19","author":"Lippi","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107763_b1115","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1586\/14760584.2015.1068124","article-title":"Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy","volume":"14","author":"Zheng","year":"2015","journal-title":"Expert Rev. Vacc."},{"key":"10.1016\/j.intimp.2021.107763_b1120","doi-asserted-by":"crossref","unstructured":"N. Nieuwenhuizen, S. Kaufmann, Next-generation vaccines based on Bacille Calmette-Gu\u00e9rin. Front Immunol 2018; 9: 121, PUBMED, 2018.","DOI":"10.3389\/fimmu.2018.00121"},{"key":"10.1016\/j.intimp.2021.107763_b1125","doi-asserted-by":"crossref","unstructured":"R.J. Arts, S.J. Moorlag, B. Novakovic, Y. Li, S.-Y. Wang, M. Oosting, V. Kumar, R.J. Xavier, C. Wijmenga, L.A. Joosten, BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity, Cell Host Microbe 23(1) (2018) 89\u2013100.e5.","DOI":"10.1016\/j.chom.2017.12.010"},{"key":"10.1016\/j.intimp.2021.107763_b1130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1749-6632.1989.tb27366.x","article-title":"New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Gu\u00e9rin into a multivaccine vehicle","volume":"569","author":"Bloom","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2021.107763_b1135","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1080\/21645515.2019.1571891","article-title":"Vaccination perspectives among adolescents and their desired role in the decision-making process","volume":"15","author":"Herman","year":"2019","journal-title":"Hum. Vacc. Immunotherap."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-08659-3","article-title":"Outcomes of controlled human malaria infection after BCG vaccination","volume":"10","author":"Walk","year":"2019","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.intimp.2021.107763_b1145","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2021.107763_b1150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2010.10.066","article-title":"Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains","volume":"29","author":"Ho","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2021.107763_b1155","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3389\/fimmu.2019.01144","article-title":"Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants","volume":"10","author":"Kumar","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b1160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000355628","article-title":"Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity","volume":"6","author":"Kleinnijenhuis","year":"2014","journal-title":"J. Innate Immun."},{"issue":"6","key":"10.1016\/j.intimp.2021.107763_b1165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nri.2016.43","article-title":"Harnessing the beneficial heterologous effects of vaccination","volume":"16","author":"Goodridge","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b1170","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1228","article-title":"Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Gu\u00e9rin vaccine: mechanisms, challenges and perspectives","volume":"9","author":"Sohrabi","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.042","article-title":"Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection","author":"Netea","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2021.107763_b1180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.smim.2018.06.002","article-title":"Non-specific Effects of Vaccines: Current Evidence And potential","volume":"2018","author":"Bree","year":"2018","journal-title":"Implic. Semin. Immunol."},{"issue":"6284","key":"10.1016\/j.intimp.2021.107763_b1185","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107763_b1190","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268820001569","article-title":"Bacillus Calmette-Gu\u00e9rin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study","volume":"148","author":"Weng","year":"2020","journal-title":"Epidemiol. Infect."},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b1195","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s10038-020-0808-9","article-title":"SARS-CoV-2 genomic variations associated with mortality rate of COVID-19","volume":"65","author":"Toyoshima","year":"2020","journal-title":"J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.intimp.2021.107763_b1200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cei.13507","article-title":"Factors determining COVID-19 pneumonia severity in a country with routine BCG vaccination","volume":"202","author":"Aksu","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2021.107763_b1205","doi-asserted-by":"crossref","unstructured":"L.E. Escobar, A. Molina-Cruz, C. Barillas-Mury, BCG vaccine protection from severe coronavirus disease 2019 (COVID-19), Proc. Natl. Acad. Sci. 117(30) (2020) 17720\u201317726.","DOI":"10.1073\/pnas.2008410117"},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b1210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4161\/hv.22218","article-title":"Plant-derived virus-like particles as vaccines","volume":"9","author":"Chen","year":"2013","journal-title":"Hum. Vacc. Immunotherap."},{"issue":"8","key":"10.1016\/j.intimp.2021.107763_b1215","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1094\/MPMI-21-8-1015","article-title":"Nicotiana benthamiana: its history and future as a model for plant\u2013pathogen interactions","volume":"21","author":"Goodin","year":"2008","journal-title":"Mol. Plant Microbe Interact."},{"issue":"1","key":"10.1016\/j.intimp.2021.107763_b1220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1558-5646.2012.01748.x","article-title":"Reconstructing the complex evolutionary origin of wild allopolyploid tobaccos (Nicotiana section Suaveolentes), Evolution: International Journal of Organic","volume":"67","author":"Kelly","year":"2013","journal-title":"Evolution"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2021.107763_b1225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01984288","article-title":"Relation degrees and phylesis of certain Nicotiana species determined by cytogenetic analysis","volume":"22","author":"Kostoff","year":"1940","journal-title":"Genetica"},{"key":"10.1016\/j.intimp.2021.107763_b1230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-phyto-080417-050141","article-title":"The Rise and Rise of Nicotiana benthamiana: A Plant for All Reasons","volume":"56","author":"Bally","year":"2018","journal-title":"Annu. Rev. Phytopathol."},{"key":"10.1016\/j.intimp.2021.107763_b1235","doi-asserted-by":"crossref","unstructured":"B.J. Ward, P. Gobeil, A. Seguin, J. Atkins, I. Boulay, P.-Y. Charbonneau, M. Couture, M.-A. D'Aoust, J. Dhaliwall, C. Finkle, Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants, medRxiv (2020).","DOI":"10.1101\/2020.11.04.20226282"},{"issue":"12","key":"10.1016\/j.intimp.2021.107763_b1240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry","year":"2010","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.intimp.2021.107763_b1245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216533","article-title":"Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate\u2014Two randomized Phase II clinical trials in 18 to 49 and\u2265 50 years old adults","volume":"14","author":"Pillet","year":"2019","journal-title":"PLoS ONE"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:07:56Z","timestamp":1727291276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921003994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":249,"alternative-id":["S1567576921003994"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107763","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107763"}}